iTeos Therapeutics, Inc. (ITOS)
NASDAQ: ITOS · Real-Time Price · USD
8.97
+0.16 (1.82%)
Nov 4, 2024, 4:00 PM EST - Market closed
iTeos Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for iTeos Therapeutics stock have an average target of 32.5, with a low estimate of 24 and a high estimate of 46. The average target predicts an increase of 262.32% from the current stock price of 8.97.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 16, 2024.
Analyst Ratings
The average analyst rating for ITOS stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +412.82% | Sep 16, 2024 |
| Wells Fargo | Wells Fargo | Buy Initiates $31 | Buy | Initiates | $31 | +245.60% | Aug 13, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $27 → $24 | Buy | Maintains | $27 → $24 | +167.56% | Aug 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $44 → $46 | Strong Buy | Maintains | $44 → $46 | +412.82% | May 13, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $29 → $27 | Buy | Maintains | $29 → $27 | +201.00% | Mar 12, 2024 |
Financial Forecast
Revenue This Year
46.75M
from 12.60M
Increased by 271.18%
Revenue Next Year
6.83M
from 46.75M
Decreased by -85.39%
EPS This Year
-4.06
from -3.15
EPS Next Year
-5.97
from -4.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 105.0M | 38.9M | 99.6M | ||
| Avg | 46.8M | 6.8M | 28.5M | ||
| Low | 34.3M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 733.7% | -16.9% | 1,358.6% | ||
| Avg | 271.2% | -85.4% | 316.8% | ||
| Low | 172.3% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.49 | -3.79 | -4.04 | ||
| Avg | -4.06 | -5.97 | -5.39 | ||
| Low | -5.80 | -8.18 | -7.91 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.